

E Shelley Hwang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6497060/publications.pdf>

Version: 2024-02-01

123
papers

7,827
citations

109321

35
h-index

56724

83
g-index

127
all docs

127
docs citations

127
times ranked

12649
citing authors

#	ARTICLE	IF	CITATIONS
1	Disparities at the Intersection of Race and Ethnicity: Examining Trends and Outcomes in Hispanic Women With Breast Cancer. <i>JCO Oncology Practice</i> , 2022, 18, e827-e838.	2.9	19
2	Metastatic breast cancer: Who benefits from surgery?. <i>American Journal of Surgery</i> , 2022, 223, 81-93.	1.8	6
3	Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma. <i>Cell</i> , 2022, 185, 299-310.e18.	28.9	161
4	Prediction of Upstaging in Ductal Carcinoma in Situ Based on Mammographic Radiomic Features. <i>Radiology</i> , 2022, 303, 54-62.	7.3	17
5	A multi-modal exploration of heterogeneous physicochemical properties of DCIS breast microcalcifications. <i>Analyst</i> , 2022, 147, 1641-1654.	3.5	5
6	œœIs it cancer or not?œœ A qualitative exploration of survivor concerns surrounding the diagnosis and treatment of ductal carcinoma in situ. <i>Cancer</i> , 2022, 128, 1676-1683.	4.1	6
7	More Than Incremental: Harnessing Machine Learning to Predict Breast Cancer Risk. <i>Journal of Clinical Oncology</i> , 2022, , JCO2102733.	1.6	0
8	Estimation of Breast Cancer Overdiagnosis in a U.S. Breast Screening Cohort. <i>Annals of Internal Medicine</i> , 2022, 175, 471-478.	3.9	49
9	Development of a new adapted QuinteT Recruitment Intervention (QRI-Two) for rapid application to RCTs underway with enrolment shortfallsœœ to identify previously hidden barriers and improve recruitment. <i>Trials</i> , 2022, 23, 258.	1.6	10
10	Immunosuppressive glycoproteins associate with breast tumor fibrosis and aggression. <i>Matrix Biology Plus</i> , 2022, 14, 100105.	3.5	5
11	Automated Dcis Identification From Multiplex Immunohistochemistry Using Generative Adversarial Networks. , 2022, , .		1
12	Outcomes and Costs for Women After Breast Cancer: Preparing for Improved Survivorship of Medicare Beneficiaries. <i>JCO Oncology Practice</i> , 2021, 17, e469-e478.	2.9	8
13	Tumour-associated macrophages drive stromal cell-dependent collagen crosslinking and stiffening to promote breast cancer aggression. <i>Nature Materials</i> , 2021, 20, 548-559.	27.5	125
14	Patientœœreported causes of distress predict disparities in time to evaluation and time to treatment after breast cancer diagnosis. <i>Cancer</i> , 2021, 127, 757-768.	4.1	21
15	Mixed-Methods Study to Predict Upstaging of DCIS to Invasive Disease on Mammography. <i>American Journal of Roentgenology</i> , 2021, 216, 903-911.	2.2	7
16	Unmasking the immune microecology of ductal carcinoma in situ with deep learning. <i>Npj Breast Cancer</i> , 2021, 7, 19.	5.2	20
17	Patient Preferences for Outcomes Following DCIS Management Strategies: A Discrete Choice Experiment. <i>JCO Oncology Practice</i> , 2021, 17, e1639-e1648.	2.9	4
18	Characterizing participants in the North Carolina Breast and Cervical Cancer Control Program: A retrospective review of 90,000 women. <i>Cancer</i> , 2021, 127, 2515-2524.	4.1	3

#	ARTICLE	IF	CITATIONS
19	Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021, 28, 5960-5971.	1.5	22
20	Matrix compliance permits NF- κ B activation to drive therapy resistance in breast cancer. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	27
21	ASO Visual Abstract: Factors Associated with Nodal Pathologic Complete Response Among Breast Cancer Patients Treated with Neoadjuvant Chemotherapy: Results of CALGB 40601 (HER2+) and 40603 (Triple-Negative) (Alliance). <i>Annals of Surgical Oncology</i> , 2021, 28, 436-437.	1.5	0
22	Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 7441-7449.	1.5	10
23	Association of Smartphone Ownership and Internet Use With Markers of Health Literacy and Access: Cross-sectional Survey Study of Perspectives From Project PLACE (Population Level Approaches to) Tj ETQq1 1 0.7843 14 rgBT7Overl	1.5	17
24	A new method to accurately identify single nucleotide variants using small FFPE breast samples. <i>Briefings in Bioinformatics</i> , 2021, 22, .	6.5	4
25	Mortality in Older Patients with Breast Cancer Undergoing Breast Surgery: How Low is "Low Risk"? <i>Annals of Surgical Oncology</i> , 2021, 28, 5758-5767.	1.5	4
26	Cellphone enabled point-of-care assessment of breast tumor cytology and molecular HER2 expression from fine-needle aspirates. <i>Npj Breast Cancer</i> , 2021, 7, 85.	5.2	8
27	ASO Visual Abstract: Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 524.	1.5	0
28	Contralateral Axillary Nodal Metastases: Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer?. <i>Annals of Surgical Oncology</i> , 2021, 28, 5544-5552.	1.5	13
29	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. <i>Journal of Clinical Oncology</i> , 2021, 39, 2720-2731.	1.6	52
30	ASO Visual Abstract: Mortality in Older Patients with Breast Cancer Undergoing Breast Surgery" How Low is "Low Risk"? <i>Annals of Surgical Oncology</i> , 2021, 28, 645-645.	1.5	1
31	Long-term risk of subsequent ipsilateral lesions after surgery with or without radiotherapy for ductal carcinoma in situ of the breast. <i>British Journal of Cancer</i> , 2021, 125, 1443-1449.	6.4	6
32	ASO Visual Abstract: Contralateral Axillary Nodal Metastases" Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer?. <i>Annals of Surgical Oncology</i> , 2021, 28, 608-609.	1.5	0
33	Mobile Health Application for Patients Undergoing Breast Cancer Surgery: Feasibility Study. <i>JCO Oncology Practice</i> , 2021, 17, e1344-e1353.	2.9	14
34	Breast cancer-derived DAMPs enhance cell invasion and metastasis, while nucleic acid scavengers mitigate these effects. <i>Molecular Therapy - Nucleic Acids</i> , 2021, 26, 1-10.	5.1	11
35	Implications for Breast Cancer Restaging Based on the 8th Edition AJCC Staging Manual. <i>Annals of Surgery</i> , 2020, 271, 169-176.	4.2	65
36	Response to Habel and Buist. <i>Journal of the National Cancer Institute</i> , 2020, 112, 216-217.	6.3	0

#	ARTICLE	IF	CITATIONS
37	Nodal Response to Neoadjuvant Chemotherapy Predicts Receipt of Radiation Therapy After Breast Cancer Diagnosis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 377-389.	0.8	13
38	Axillary lymph node dissection in node-positive breast cancer: are ten nodes adequate and when is enough, enough?. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 661-670.	2.5	12
39	A Case-Control Study Examining Disparities in Clinical Trial Participation Among Breast Surgical Oncology Patients. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz103.	2.9	17
40	Surgery for Men with Breast Cancer: Do the Same Data Still Apply?. <i>Annals of Surgical Oncology</i> , 2020, 27, 4720-4729.	1.5	7
41	It's not you, it's me: The influence of patient and surgeon gender on patient satisfaction scores. <i>American Journal of Surgery</i> , 2020, 220, 1179-1188.	1.8	9
42	Impact of adjuvant trastuzumab on locoregional failure rates in a randomized clinical trial: North Central Cancer Treatment Group N9831 (alliance) study. <i>Cancer</i> , 2020, 126, 5239-5246.	4.1	1
43	A medicare-based comparative mortality analysis of active surveillance in older women with DCIS. <i>Npj Breast Cancer</i> , 2020, 6, 57.	5.2	5
44	De-Escalating Breast Cancer Surgery for Low-Risk Ductal Carcinoma in Situ. <i>JAMA Oncology</i> , 2020, 6, 1117.	7.1	3
45	Surgical Management of the Axilla in Elderly Women With Node-Positive Breast Cancer. <i>Journal of Surgical Research</i> , 2020, 254, 275-285.	1.6	7
46	Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change. <i>Annals of Surgical Oncology</i> , 2020, 27, 2600-2613.	1.5	31
47	The Evolution of Breast Satisfaction and Well-Being after Breast Cancer: A Propensity-Matched Comparison to the Norm. <i>Plastic and Reconstructive Surgery</i> , 2020, 145, 595-604.	1.4	15
48	Pain Control in Breast Surgery: Survey of Current Practice and Recommendations for Optimizing Management—American Society of Breast Surgeons Opioid/Pain Control Workgroup. <i>Annals of Surgical Oncology</i> , 2020, 27, 985-990.	1.5	23
49	Breast cancer tumor histopathology, stage at presentation, and treatment in the extremes of age. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 227-235.	2.5	34
50	Predicting Upstaging of DCIS to Invasive Disease: Radiologists's Predictive Performance. <i>Academic Radiology</i> , 2020, 27, 1580-1585.	2.5	4
51	Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 207-217.	2.5	17
52	The Human Tumor Atlas Network: Charting Tumor Transitions across Space and Time at Single-Cell Resolution. <i>Cell</i> , 2020, 181, 236-249.	28.9	334
53	Derivation of a nuclear heterogeneity image index to grade DCIS. <i>Computational and Structural Biotechnology Journal</i> , 2020, 18, 4063-4070.	4.1	8
54	A Novel Staging System for De Novo Metastatic Breast Cancer Refines Prognostic Estimates. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	4.2	15

#	ARTICLE	IF	CITATIONS
55	Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217. <i>Journal of Clinical Investigation</i> , 2020, 130, 5721-5737.	8.2	73
56	Do Histopathology and Clinical Outcomes of Breast Atypia Vary by Race/Ethnicity?. <i>Journal of Surgical Research</i> , 2020, 255, 205-215.	1.6	2
57	Examining Peripheral and Tumor Cellular Immune in Patients With Cancer. <i>Frontiers in Immunology</i> , 2019, 10, 1767.	4.8	44
58	Ductal Carcinoma In Situ Management: All or Nothing, or Something in between?. <i>Current Breast Cancer Reports</i> , 2019, 11, 190-202.	1.0	0
59	Ductal carcinoma in situ: to treat or not to treat, that is the question. <i>British Journal of Cancer</i> , 2019, 121, 285-292.	6.4	168
60	DCIS with Microinvasion: Is It In Situ or Invasive Disease?. <i>Annals of Surgical Oncology</i> , 2019, 26, 3124-3132.	1.5	36
61	Perspectives on the Costs of Cancer Care: A Survey of the American Society of Breast Surgeons. <i>Annals of Surgical Oncology</i> , 2019, 26, 3141-3151.	1.5	20
62	Clinical and pathological stage discordance among 433,514 breast cancer patients. <i>American Journal of Surgery</i> , 2019, 218, 669-676.	1.8	13
63	Decreasing rates of axillary lymph node dissections over time: Implications for surgical resident exposure and operative skills development. <i>American Journal of Surgery</i> , 2019, 218, 786-791.	1.8	12
64	Deep learning analysis of breast MRIs for prediction of occult invasive disease in ductal carcinoma in situ. <i>Computers in Biology and Medicine</i> , 2019, 115, 103498.	7.0	45
65	Incidence of Ductal Carcinoma <i>In Situ</i> in the United States, 2000–2014. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2019, 28, 1316-1323.	2.5	22
66	Growth Dynamics of Mammographic Calcifications: Differentiating Ductal Carcinoma in Situ from Benign Breast Disease. <i>Radiology</i> , 2019, 292, 77-83.	7.3	19
67	The effect of treatment on patient-reported distress after breast cancer diagnosis. <i>Cancer</i> , 2019, 125, 3040-3049.	4.1	10
68	The Influence of Age on the Histopathology and Prognosis of Atypical Breast Lesions. <i>Journal of Surgical Research</i> , 2019, 241, 188-198.	1.6	5
69	Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets. <i>Cancer Cell</i> , 2019, 35, 588-602.e10.	16.8	636
70	Variability in diagnostic threshold for comedo necrosis among breast pathologists: implications for patient eligibility for active surveillance trials of ductal carcinoma in situ. <i>Modern Pathology</i> , 2019, 32, 1257-1262.	5.5	27
71	The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS). <i>BMJ Open</i> , 2019, 9, e026797.	1.9	182
72	Cancer Outcomes in DCIS Patients Without Locoregional Treatment. <i>Journal of the National Cancer Institute</i> , 2019, 111, 952-960.	6.3	76

#	ARTICLE	IF	CITATIONS
73	Identification of the Fraction of Indolent Tumors and Associated Overdiagnosis in Breast Cancer Screening Trials. <i>American Journal of Epidemiology</i> , 2019, 188, 197-205.	3.4	12
74	Reframing the conversation about contralateral prophylactic mastectomy: Preparing women for postsurgical realities. <i>Psycho-Oncology</i> , 2019, 28, 394-400.	2.3	15
75	Surgical Resection of the Primary Tumor in Women With De Novo Stage IV Breast Cancer. <i>Annals of Surgery</i> , 2019, 269, 537-544.	4.2	89
76	Prediction of Occult Invasive Disease in Ductal Carcinoma in Situ Using Deep Learning Features. <i>Journal of the American College of Radiology</i> , 2018, 15, 527-534.	1.8	56
77	The Effect of Hospital Volume on Breast Cancer Mortality. <i>Annals of Surgery</i> , 2018, 267, 375-381.	4.2	67
78	Anatomy and Breast Cancer Staging. <i>Surgical Oncology Clinics of North America</i> , 2018, 27, 51-67.	1.5	20
79	Molecular determinants of post-mastectomy breast cancer recurrence. <i>Npj Breast Cancer</i> , 2018, 4, 34.	5.2	9
80	Association of Low Nodal Positivity Rate Among Patients With ERBB2-Positive or Triple-Negative Breast Cancer and Breast Pathologic Complete Response to Neoadjuvant Chemotherapy. <i>JAMA Surgery</i> , 2018, 153, 1120.	4.3	96
81	The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT). <i>Annals of Surgery</i> , 2018, 268, 591-601.	4.2	125
82	Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database. <i>Annals of Surgical Oncology</i> , 2018, 25, 2249-2260.	1.5	77
83	Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. <i>Annals of Surgical Oncology</i> , 2018, 25, 2890-2898.	1.5	24
84	The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations. <i>Annals of Surgical Oncology</i> , 2018, 25, 2807-2812.	1.5	13
85	How Low Can We Go and Should We? Risk Reduction for Minimal-Volume DCIS. <i>Annals of Surgical Oncology</i> , 2018, 25, 354-355.	1.5	2
86	Can algorithmically assessed MRI features predict which patients with a preoperative diagnosis of ductal carcinoma in situ are upstaged to invasive breast cancer?. <i>Journal of Magnetic Resonance Imaging</i> , 2017, 46, 1332-1340.	3.4	19
87	Can Occult Invasive Disease in Ductal Carcinoma In Situ Be Predicted Using Computer-extracted Mammographic Features?. <i>Academic Radiology</i> , 2017, 24, 1139-1147.	2.5	18
88	Contralateral Prophylactic Mastectomy. <i>JAMA Surgery</i> , 2017, 152, 282.	4.3	2
89	Classifying the evolutionary and ecological features of neoplasms. <i>Nature Reviews Cancer</i> , 2017, 17, 605-619.	28.4	303
90	Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011. <i>Annals of Surgical Oncology</i> , 2017, 24, 3559-3566.	1.5	18

#	ARTICLE	IF	CITATIONS
91	Imaging Features of Patients Undergoing Active Surveillance for Ductal Carcinoma in Situ. <i>Academic Radiology</i> , 2017, 24, 1364-1371.	2.5	11
92	Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials. <i>Annals of Surgical Oncology</i> , 2017, 24, 3534-3540.	1.5	76
93	Fat Grafting—More Than Just the Hype. <i>JAMA Surgery</i> , 2017, 152, 951.	4.3	3
94	Suspicious breast calcifications undergoing stereotactic biopsy in women ages 70 and over: Breast cancer incidence by BI-RADS descriptors. <i>European Radiology</i> , 2017, 27, 2275-2281.	4.5	13
95	Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ. <i>Annals of Surgical Oncology</i> , 2017, 24, 660-668.	1.5	21
96	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. <i>Annals of Surgical Oncology</i> , 2017, 24, 38-51.	1.5	80
97	Editorial: What Can Molecular Diagnostics Add to Locoregional Treatment Recommendations for DCIS?. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	1
98	Cost Implications of an Evidence-Based Approach to Radiation Treatment After Lumpectomy for Early-Stage Breast Cancer. <i>Journal of Oncology Practice</i> , 2017, 13, e283-e290.	2.5	24
99	DNA defects, epigenetics, and gene expression in cancer-adjacent breast: a study from The Cancer Genome Atlas. <i>Npj Breast Cancer</i> , 2016, 2, 16007.	5.2	33
100	Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update. <i>Practical Radiation Oncology</i> , 2016, 6, e219-e234.	2.1	132
101	The Impact of the Affordable Care Act on North Carolinian Breast Cancer Patients Seeking Financial Support for Treatment. <i>Annals of Surgical Oncology</i> , 2016, 23, 3412-3417.	1.5	3
102	Active Surveillance for DCIS: The Importance of Selection Criteria and Monitoring. <i>Annals of Surgical Oncology</i> , 2016, 23, 4134-4136.	1.5	19
103	Can Vascular Patterns on Preoperative Magnetic Resonance Imaging Help Predict Skin Necrosis after Nipple-Sparing Mastectomy?. <i>Journal of the American College of Surgeons</i> , 2016, 223, 279-285.	0.5	14
104	Prognostic Impact of 21-Gene Recurrence Score in Patients With Stage IV Breast Cancer: TBCRC 013. <i>Journal of Clinical Oncology</i> , 2016, 34, 2359-2365.	1.6	60
105	Reoperation for Margins After Breast Conservation Surgery. <i>JAMA Surgery</i> , 2016, 151, 656.	4.3	2
106	Imaging-Guided Core-Needle Breast Biopsy: Impact of Meditation and Music Interventions on Patient Anxiety, Pain, and Fatigue. <i>Journal of the American College of Radiology</i> , 2016, 13, 526-534.	1.8	77
107	Outcomes of Active Surveillance for Ductal Carcinoma in Situ: A Computational Risk Analysis. <i>Journal of the National Cancer Institute</i> , 2016, 108, djv372.	6.3	57
108	Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC) Tj ETQq0 0 0.6BT /Overlock 10 T	0.6	10

#	ARTICLE	IF	CITATIONS
109	A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer. <i>Science Translational Medicine</i> , 2016, 8, 320ra4.	12.4	224
110	Contemporary management of ductal carcinoma in situ and lobular carcinoma in situ. <i>Chinese Clinical Oncology</i> , 2016, 5, 32-32.	1.2	7
111	Impact of delayed lymphoscintigraphy for sentinel lymphnode biopsy for breast cancer. <i>Journal of Surgical Oncology</i> , 2015, 111, 931-934.	1.7	11
112	Preoperative Single-Fraction Partial Breast Radiation Therapy: A Novel Phase 1, Dose-Escalation Protocol With Radiation Response Biomarkers. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 846-855.	0.8	113
113	Trends in Treatment Patterns and Outcomes for Ductal Carcinoma In Situ. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv263.	6.3	156
114	Lobular breast cancer series: imaging. <i>Breast Cancer Research</i> , 2015, 17, 94.	5.0	107
115	Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic Cells. <i>Cancer Cell</i> , 2014, 26, 623-637.	16.8	751
116	Patterns of Breast Magnetic Resonance Imaging Use. <i>JAMA Internal Medicine</i> , 2014, 174, 122.	5.1	7
117	Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. <i>Nature Medicine</i> , 2014, 20, 360-367.	30.7	353
118	Satisfaction with treatment decision-making and treatment regret among Latinas and non-Latina whites with DCIS. <i>Patient Education and Counseling</i> , 2014, 94, 83-89.	2.2	36
119	New Treatment Paradigms for Patients with Ductal Carcinoma In Situ. <i>Current Breast Cancer Reports</i> , 2013, 5, 86-98.	1.0	0
120	Reply to survival after lumpectomy and mastectomy for early stage invasive breast cancer: The effect of age and hormone receptor status. <i>Cancer</i> , 2013, 119, 3254-3255.	4.1	3
121	Survival after lumpectomy and mastectomy for early stage invasive breast cancer. <i>Cancer</i> , 2013, 119, 1402-1411.	4.1	216
122	Reframing treatment for ductal carcinoma in situ: could less be more?. <i>Bulletin of the American College of Surgeons</i> , 2012, 97, 50-1.	0.3	1
123	Leukocyte Complexity Predicts Breast Cancer Survival and Functionally Regulates Response to Chemotherapy. <i>Cancer Discovery</i> , 2011, 1, 54-67.	9.4	1,486